A Phase 3 interventional study of Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified and Dextrose, 5% in Water in Immunologic Deficiency Syndrome, Agammaglobulinemia and Severe Combined Immunodeficiency, sponsored by Grifols Therapeutics LLC. Completed at 13 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-09-25.
Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Immunologic Deficiency Syndromes with a site in United States — 27 open to participants now, 34 under way, none of them phase 3. Immunologic Deficiency Syndromes · United States.
Among the 127 studies in Immunologic Deficiency Syndromes with a site in United States, this one is the 5th largest by enrollment of the 77 interventional ones that give a count, is one of 6 that started in 2002, is one of 8 in phase 3, and was the 27th registered.
204 studies on the registry are indexed under Immunologic Deficiency Syndromes; 50 are open to participants now.
Browse Immunologic Deficiency Syndromes studies →27 of the 127 studies in Immunologic Deficiency Syndromes with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 1–120 · Healthy volunteers
Henry M. Jackson Foundation for the Advancement of Military Medicine · Sites in United States
Ages 4+
Monica Bhatia · Sites in United States
Ages 3 mo–26 yrs
Children's Hospital of Philadelphia · Sites in United States
Ages 1 mo–25 yrs
Washington University School of Medicine · Sites in United States
Ages 8+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Immunologic Deficiency Syndromes studies recruiting now, 19 (44%) set no upper age limit and 14 (33%) stop at 75 or younger; 30 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 40 · Phase 3 10 · Phase 4 2
First in 1977; this study’s year is marked. 6 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 30 across 123 interventional studies indexed under Immunologic Deficiency Syndromes.
Median enrollment 28 across the 77 interventional studies, 142 across the 45 observational. Of the 83 that completed or were terminated, 28 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 127 have an industry lead sponsor. The 10 most frequent:
This study is registered under Grifols Therapeutics LLC, one of the names counted as Grifols. Under that name alone:
Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Grifols has 3 studies filed under Immunologic Deficiency Syndromes — fewer than ten, so there is no comparison to draw.
9 of the studies in Immunologic Deficiency Syndromes with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02356653Children's Hospital of PhiladelphiaExpanded Access Protocol Using CD3+/CD19+ Depleted PBSC | 2027-01 |
| NCT05584488Columbia UniversityAllergy and Immunology Natural History Study | 2027-01 |
| NCT05333471National Institute of Allergy and Infectious Diseases (NIAID)Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis | 2027-03-01 |
| NCT04554914Pierre Fabre MedicamentA Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases | 2027-06 |
| NCT01666080Masonic Cancer Center, University of MinnesotaSecond or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC) | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 127 studies in Immunologic Deficiency Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to determine if the safety and tolerability of Immune Globulin Intravenous (Human), 10% caprylate/chromatography (IGIV-C)purified is similar when infused at two different infusion rates. The primary objective is to compare the incidence and severity of all infusion related adverse events when IGIV-C, 10% is administered at a rate of 0.14 mL/kg/min compared to a rate of 0.08 mL/kg/min after a single daily infusion.
This is a prospective, single blind, randomized, multi-center cross-over trial in patients with Primary Immune Deficiency. Patients with a confirmed diagnosis of primary Immune Deficiency will be treated with two daily infusions given 3-4 weeks apart at the fixed individual IGIV dose regimen (400-600 mg/kg) established prior to entry into the study. Any subject with an established dose in the range of 200-399 mg/kg will be assigned to receive 400 mg/kg during the course of the study during the same dosing schedule established prior to entry into the study.
After a screening period lasting not more than four weeks, patients will be randomized into one of two cross-over groups. Patients randomized to Group 1 will receive their first IGIV-C, 10% dose at a rate of 0.08 mL/kg/min and their second infusion at a rate of 0.14 mL/kg/min, whereas patients randomized to Group 2 will receive IGIV-C, 10% at a rate of 0.14 mL/kg/min on the first infusion day and then 0.08 mL/kg/min on the second infusion day. All patients just prior to each IGIV-C, 10% infusion will receive the same volume of 5% dextrose as calculated for their IGIV-C, 10% infusion and given at a target rate according to the schema below.
Group 1:
Group 2:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infusion #1 (Week 0)Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min) ; Infusion #2 (Week 3-4)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min)
Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified · Drug: Dextrose, 5% in Water
Infusion #1 (Week 0)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min); Infusion #2 Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min)
Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified · Drug: Dextrose, 5% in Water
Drug page: Immunoglobulins, Intravenous
Also known as: Gamunex, IGIVnex, Gaminex, IGIV-C, Immune Globulin Intravenous (Human) , 10%, IGIV, BAY 41-1000, TAL-05-00004
Infusion related adverse events
Time frame: within 72 hours after infusion
All adverse events
Time frame: within 72 hours after infusion
The record gives a start of Aug 2002, a primary completion of Aug 2002 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous
Immunologic Deficiency Syndromes →